AMTI Applied Molecular Transport Inc.

Biotech Analyst Ratings

Latest News

1. 09 May 2022 Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update

   Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis
   

   • Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3
     

   Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance

   SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

   "We were pleased to recently announce positive top-line data from our FILLMORE trial in chronic pouchitis patients, the first of four important AMT-101…

   View Full Article
2. 05 May 2022 Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference

   SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday, May 10, 2022 at 2:20 p.m. ET (11:20 a.m. PT).
   

   A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.

   About Applied Molecular Transport Inc.

   AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product…

   View Full Article
3. 25 April 2022 Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

   –  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)
   –  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile
   –  Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups
   –  Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis
   –  Further substantiates potential of AMT-101 and Company's oral biologics platform
   –  Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT)

   SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today…

   View Full Article
4. 24 April 2022 Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

   - Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT)

   SOUTH SAN FRANCISCO, Calif., April 24, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 FILLMORE monotherapy trial for AMT-101 (GI- selective, oral fusion of IL-10) in patients with chronic pouchitis in a premarket press release and webcasted conference call on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT).

   Conference Call & Webcast Information
   To participate in the conference call, please dial (844) 422-9742 (Domestic) or (706) 758-6032 (International) and refer to conference ID 5649019. The live webcast will be accessible…

   View Full Article
5. 13 April 2022 Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company's Proprietary Technology Platform

   Publication describes critical interactions between cholix-based transport domain and endogenous intracellular trafficking pathways used by Company's proprietary biologic product candidates to cross intestinal epithelial barrier
   

   Deep characterization of natural molecular trafficking mechanisms provides novel pathway biology insights, furthers Company's technology platform to address a wider range of disease targets and strengthens wholly-owned IP portfolio

   SOUTH SAN FRANCISCO, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that new insights into the unique mechanism of action utilized by its oral biologic product candidates, including…

   View Full Article